- Conditions
- Contraception
- Interventions
- Ulipristal Acetate, Levonorgestrel (LNG)/Ethinyl estradiol birth control pill
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 887
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypogonadism, Gender Identity Dysphoria
- Interventions
- Fortesta, Estradiol
- Drug
- Lead sponsor
- Walter Reed National Military Medical Center
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma
- Interventions
- IDE574, Fulvestrant injection
- Drug
- Lead sponsor
- IDEAYA Biosciences
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 11
- States / cities
- Plantation, Florida • East Brunswick, New Jersey • Lake Success, New York + 7 more
- Conditions
- Cerebrospinal Fluid Leak
- Interventions
- Suturable DuraGen™
- Device
- Lead sponsor
- Integra LifeSciences Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Portland, Oregon
- Conditions
- Healthy Volunteers
- Interventions
- Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent), CC-99677
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 48 Years · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Miami, Florida • Marlton, New Jersey • Austin, Texas
- Conditions
- Transgender Persons
- Interventions
- Estradiol
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Perimenopausal Depression, Post Menopausal, Healthy, Depression
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 45 Years to 65 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cardiovascular Risk Reduction
- Interventions
- Estradiol 100 Micrograms Patch, Estradiol Patch
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years to 45 Years · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Cancer, Cancer of the Breast, Neoplasms, Breast
- Interventions
- Estrace, Anastrozole
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Voorhees Township, New Jersey • Philadelphia, Pennsylvania
- Conditions
- Metastatic Breast Cancer
- Interventions
- 17B-estradiol, Letrozole, Anastrozole, Exemestane
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 3
- States / cities
- Springfield, Massachusetts • Rochester, Minnesota • Lebanon, New Hampshire
- Conditions
- Breast Cancer
- Interventions
- Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Infertility
- Interventions
- dehydroepiandrosterone
- Dietary Supplement
- Lead sponsor
- Virginia Center for Reproductive Medicine
- Other
- Eligibility
- 21 Years to 44 Years · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Reston, Virginia
- Conditions
- Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk
- Interventions
- Relugolix + Estradiol + Norethindrone Acetate
- Drug
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Marlborough, Massachusetts
- Conditions
- Uterine Hemorrhage, Menorrhagia
- Interventions
- Provera, Combination Birth Control pills
- Drug
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Solid Tumors
- Interventions
- dovitinib, fulvestrant
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- Las Vegas, Nevada • The Bronx, New York
- Conditions
- Contraception
- Interventions
- NES/EE CVR
- Combination Product
- Lead sponsor
- Population Council
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 1,135 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2014
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Francisco, California • Chicago, Illinois + 2 more
- Conditions
- Breast Cancer, Quality of Life
- Interventions
- Accelerated Partial Breast Irradiation (APBI), tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene
- Radiation · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 65 Years and older · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Interventions
- XL102, Fulvestrant, Abiraterone, Prednisone
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more
- Conditions
- Transgenderism
- Interventions
- Transdermal patch, Pro-thrombotic markers, Metabolic markers, Hormone Profile, Daily Sublingual Tablet, BID Sublingual Tablet, Spironolactone
- Drug · Diagnostic Test
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 30 Years · Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Vasomotor Symptoms, Hot Flashes
- Interventions
- 0.5mg DRSP / 0.5mg E2 (BAY86-4891), 0.25mg DRSP / 0.5mg E2 (BAY86-4891), Estradiol (E2 0.3mg), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 735 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 76
- States / cities
- Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 64 more
- Conditions
- HIV I Infection
- Interventions
- Estradiol
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 14
- States / cities
- San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
- Conditions
- Pelvic Pain, Endometriosis
- Interventions
- Psychophysical assessment, Psychophysical assessments of experimental pain, Blood, urine and saliva samples, Biopsy and surgery-related data.
- Other · Behavioral · Diagnostic Test + 1 more
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 12 Years to 45 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- ESR-specific PET scan
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 13 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
- Interventions
- GVV858, Fulvestrant, Letrozole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Nashville, Tennessee • San Antonio, Texas